TriangleNCT02499081 · OUTCOME
Change in Serum Osteocalcin From Baseline to End of Study in Patients With Relapsed/Refractory Multiple Myeloma.
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- ng/ML
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Baseline, Treatment (28-day cycles for 6 cycles)
What was measured
To evaluate the effect of Ixazomib on inducing osteoblast activation as measured by change in serum osteocalcin from baseline to end of study in patients with relapsed/refractory multiple myeloma.
Groups in this outcome
Ixazomib
Ixazomib 4.0 mg given on days 1, 8 15, 22 of a 28 day cycle maximum of 6 cycles. Ixazomib
| Group | Source count |
|---|---|
| Ixazomib | 20 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Ixazomib | 20.00 | Not reported | 17.50 | 25.50 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 17.50
- upper Limit
- 25.50
- value
- 20.00
- denoms
- counts
- group Id
- OG000
- value
- 20
- units
- Participants
- description
- To evaluate the effect of Ixazomib on inducing osteoblast activation as measured by change in serum osteocalcin from baseline to end of study in patients with relapsed/refractory multiple myeloma.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Ixazomib 4.0 mg given on days 1, 8 15, 22 of a 28 day cycle maximum of 6 cycles. Ixazomib
- id
- OG000
- title
- Ixazomib
- param Type
- MEDIAN
- reporting Status
- POSTED
- time Frame
- Baseline, Treatment (28-day cycles for 6 cycles)
- title
- Change in Serum Osteocalcin From Baseline to End of Study in Patients With Relapsed/Refractory Multiple Myeloma.
- type
- PRIMARY
- unit Of Measure
- ng/ML
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice